Home > Insider Trading > Filing (0001209191-23-036080)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
921299	Fibrogen Inc	FGEN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1714563	Aoife Brennan	C/O Fibrogen, Inc. 409 Illinois St. San Francisco CA 94158		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-06-07	8,289	$0.00	32,680	No	4	A	Direct
Common Stock	Disposition	2023-06-09	1,994	$16.74	30,686	No	4	S	Direct
Common Stock	Disposition	2023-06-09	2,739	$17.52	27,947	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2023-06-07	12,666	$0.00	12,666	$17.13

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,666		2033-06-06	No	4	A	Direct

Footnotes

Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.17 to $17.14. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.26 to $17.72. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.